


REVIEW

Open Access



HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models

Joseph Torresi^{1*}, Bang Manh Tran², Dale Christiansen¹, Linda Earnest-Silveira¹, Renate Hilda Marianne Schwab² and Elizabeth Vincan^{2,3,4*} 

Abstract

Background: Hepatitis B virus (HBV) is the leading cause of liver cancer, but the mechanisms by which HBV causes liver cancer are poorly understood and chemotherapeutic strategies to cure liver cancer are not available. A better understanding of how HBV requisitions cellular components in the liver will identify novel therapeutic targets for HBV associated hepatocellular carcinoma (HCC).

Main body: The development of HCC involves deregulation in several cellular signalling pathways including Wnt/FZD/ β -catenin, PI3K/Akt/mTOR, IRS1/IGF, and Ras/Raf/MAPK. HBV is known to dysregulate several hepatocyte pathways and cell cycle regulation resulting in HCC development. A number of these HBV induced changes are also mediated through the Wnt/FZD/ β -catenin pathway. The lack of a suitable human liver model for the study of HBV has hampered research into understanding pathogenesis of HBV. Primary human hepatocytes provide one option; however, these cells are prone to losing their hepatic functionality and their ability to support HBV replication. Another approach involves induced-pluripotent stem (iPS) cell-derived hepatocytes. However, iPS technology relies on retroviruses or lentiviruses for effective gene delivery and pose the risk of activating a range of oncogenes. Liver organoids developed from patient-derived liver tissues provide a significant advance in HCC research. Liver organoids retain the characteristics of their original tissue, undergo unlimited expansion, can be differentiated into mature hepatocytes and are susceptible to natural infection with HBV.

Conclusion: By utilizing new ex vivo techniques like liver organoids it will become possible to develop improved and personalized therapeutic approaches that will improve HCC outcomes and potentially lead to a cure for HBV.

Keywords: Hepatitis B virus, Liver cancer, Wnt signalling, Organoids, Cell cycle

Background

Hepatitis B virus (HBV) is a major health concern in many regions of the world, where chronic carrier rates range from 10 to 20%. Despite the availability of a safe and effective vaccine, 5.2 million cases of acute infection were reported in the year 2000 and there are over 400 million chronic carriers globally. In Australia, 239,000 people are chronically infected, and there are an

estimated 90,000 people who have not been diagnosed and are unaware of their infection. Liver cancer is the second most common cause of cancer death after lung cancer. More alarmingly, while the mortality rate for most cancers has decreased significantly over the last decade and is projected to continue this sliding trend over the next 20 years, liver cancer remains one of the common cancers with an increasing death rate. The main type of liver cancer is hepatocellular carcinoma (HCC). The mortality rate from HCC is projected to increase by ~40% by 2030 (Cancer UK). Over 90% of cases of liver cancer globally have a viral aetiology, and the vast majority of these is due to chronic hepatitis B infection [1]. In fact, the recent Global Burden of

* Correspondence: joseph.t@unimelb.edu.au; evincan@unimelb.edu.au

¹Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3010, Australia

²The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3010, Australia

Full list of author information is available at the end of the article



Disease study has highlighted that total deaths caused by viral hepatitis (including liver cancer) now exceed the number of deaths caused by tuberculosis, HIV/AIDS and malaria [2].

Although HBV is a known hepatocarcinogen, the precise mechanism by which it causes HCC is unknown and the optimal therapeutic regimens for the treatment of HBV associated HCC have not yet been established. Treatment options for HCC are limited and currently Sorafenib monotherapy is the standard of care for patients with advanced HCC. However, the overall survival of patients treated with sorafenib is disappointing with the median survival of less than 3 months [3]. There is an urgent need to develop new and more effective treatments for HCC. Mounting evidence from both in vitro and in vivo studies suggest that combination therapy could be an effective approach. For example, an additive and synergistic effect of targeting the Ras/Raf/MAPK pathway in combination with other pathways important in HCC proliferation such as Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT/ mammalian target of rapamycin (mTOR) and Wnt/ β -catenin has been shown [4]. However, selecting the best, most appropriate and safest combinations, particularly for patients with HBV associated HCC and for clinical trials, remain a challenge.

Main text

HBV and hepatocarcinogenesis

The mechanism underlying the development of HBV associated HCC is multifactorial, linking changes within cell signalling pathways and cell cycle regulation, together with an inflammatory and cytokine reaction driven by antigen presenting cells in response to degradation products of apoptotic cells and viral antigens [5, 6]. Several separate signalling pathways are deregulated in HCC including the Wnt/FZD/ β -catenin, PI3K/Akt/mTOR, insulin receptor substrate 1 (IRS1)/ insulin-like growth factor 1 (IGF), and the Ras/Raf/ mitogen-activated protein kinases (MAPK) pathway (Fig. 1). Inflammation that accompanies chronic hepatitis B infection of the liver is a strong factor in the development of HCC [5, 6] and currently available therapeutic strategies for HBV are only partially effective in reducing the risk of developing HCC [7]. The X protein of HBV (HBx) has also been shown to be an important promoter of hepatocellular transformation. We have previously shown that HBV results in dysregulation of several signal transduction pathways, cell cycle [8–10] and that the HBx protein contributes to HCC development through the upregulation of suppressor of cytokine signalling 3 (SOCS3) protein [11]. Similarly, the HBV large (LHBs) and middle (MHBs) envelope proteins




Fig. 1 HBV associated HCC. HBV infection of hepatocytes is thought to impact on a number of cellular signalling pathways to regulate expression and function of genes that control cellular processes but also HBV replication and persistence, that ultimately leads to oncogenic transformation

have also been shown to contribute to hepatocarcinogenesis [12]. Furthermore, the effects of HBV on these signalling pathways are mediated through the Wnt/FZD/ β -catenin pathway [6], a critical driver of HCC development. Inflammation that accompanies chronic hepatitis B infection of the liver is a strong factor in the development of HCC [5, 13–15] and currently available therapeutic strategies for HBV are only partially effective in reducing the risk of developing HCC [16]. Kupffer cells also appear to play a central role in driving the inflammatory responses that underlie HCC development [5, 15]. While interesting, these in vitro studies suffer from the inherent drawback that their relevance to HCC caused by expression of these proteins during the normal course of viral infection is unknown.

HBV associated HCC, Wnt/FZD/ β -catenin, PI3K/AKT, IN/IRS1, and Ras/ERK1,2 pathways

Wnt/FZD/ β -catenin pathways

The Wnt cascade has emerged as a critical regulator of stem cells and activation of Wnt signalling has been associated with numerous cancers [17]. Wnt signalling is activated by the binding of one of the 19 mammalian extracellular soluble secreted Wnt ligands to single or multiple members of 10 mammalian Frizzled (FZD) receptors (Fig. 2). Binding of Wnt to FZD can lead to activation of the canonical β -catenin pathway [18, 19] or the non-canonical c-Jun N-terminal kinase (JNK) [20] and Ca^{++} pathways [21], however, here we limit our discussion to the canonical β -catenin pathway as its role is best characterised in context of liver and liver cancer.




Fig. 2 Wnt/ β -catenin signal transduction pathway. Wnt binding to the FZD/LRP5/6 receptor complex leads to inhibition of GSK3 enzyme activity and the β -catenin destruction complex, which allows newly synthesized β -catenin to accumulate and translocate to the nucleus (orange arrows), where it binds with co-factors to form a transcriptionally active complex. Wnt signalling can be inhibited at the cell surface by various naturally occurring pathway inhibitors such as sFRPs and DKK, which bind to Wnt and LRP5/6 respectively. [secreted Frizzled Related Protein (sFRP); Frizzled (FZD); Dickkopf (DKK); Glycogen Synthase Kinase 3 (GSK3); Adenomatous Polyposis Coli (APC), Casein Kinase 1 (CK1)]

In the Wnt “off” state, β -catenin is primarily involved in cell-cell adherens junctions and free cytoplasmic β -catenin is targeted for degradation by a cytoplasmic destruction complex that contains Axin, adenomatous polyposis coli (APC), glycogen synthase kinase3- β (GSK3 β) and casein kinase 1 (CK1). Sequential phosphorylation of the N-terminus of β -catenin by CK1 and GSK3 leads to recognition of β -catenin by the E3 ubiquitin ligase β -transducin repeat-containing protein (β -trcp). Ubiquitylation of β -catenin targets it for proteasomal degradation and keeps cytoplasmic and nuclear levels of β -catenin low (Fig. 3) [22]. In the “on” state, Wnt binds to FZD and its co-receptor low-density lipoprotein receptor-related protein (LRP)-5/6 to selectively activate β -catenin-mediated canonical Wnt signalling. This triggers a series of downstream events that culminates in the inhibition of the destruction complex, non-phosphorylated β -catenin accumulates in the cytoplasm, translocates to the nucleus and forms a transcriptionally active complex with the T-cell-specific transcription factor/lymphoid enhancer-binding factor (TCF/LEF) to initiate the expression of Wnt target genes (Fig. 2). The canonical Wnt/ β -catenin pathway is regulated by many naturally occurring antagonists that act to inhibit Wnt binding to FZD [for example, secreted FZD-related protein (sFRP) and Wnt inhibitory factor (WIF)] or FZD binding to LRP [for example, Dickkpsf (DKK)] (Fig. 2) [23].

Wnt signalling is involved in several physiological and pathophysiological processes during embryonic development and carcinogenesis [18, 24]. Wnt/FZD/ β -catenin signalling plays a critical role in liver development, liver regeneration and liver zonation which is required for spatial separation of the diverse metabolic functions performed in the liver [24]. Aberrant and constitutive activation of the Wnt pathway leads to uncontrolled cell proliferation and survival, promoting the development of several cancers including HCC [24] and HBV associated HCC [25]. In HCC, β -catenin accumulation has been observed in up to 50% of tumours and nuclear accumulation has been correlated with tumour progression and poor prognosis [26]. Mutations in β -catenin gene 1 (*CTNNB1*) that constitutively activate Wnt signalling have been reported in up to 40% of HCC cases [27]. The mutations at the N-terminus of the gene remove the GSK3 β /CK1 phosphorylation sites, that normally target β -catenin for proteasomal degradation and leads to its stabilisation and translocation to the nucleus (Figs. 2 and 3). Further regulation of the Wnt pathway in HCC occurs via silencing through promoter hypermethylation of genes that code for the naturally occurring inhibitors of Wnt-FZD-LRP interaction. Hypermethylation of inhibitors of the receptor ligand complex are a common feature of Wnt-addicted cancers, irrespective of mutations to down-stream components of the pathway that constitutively activate Wnt signalling [23].




Fig. 3 Targeted phosphorylation's are required for ubiquitylation and degradation of β -catenin. Axin acts as scaffold that brings CK1, GSK3 and β -catenin in close proximity. CK1 initiates the process by phosphorylating Ser45 at the N-terminus of β -catenin, followed by sequential phosphorylation at Thr41, Ser37 and Ser33 by GSK3. β -Trcp recognizes the phosphorylated residues Ser33 and Ser37, targeting β -catenin for ubiquitylation and proteasomal degradation. These regulatory phosphorylation sites are commonly mutated in liver cancer. [Casein Kinase 1 (CK1); Glycogen Synthase Kinase 3 (GSK3); β -transducin-repeat-containing protein (β -Trcp)]

The Wnt/FZD/ β -catenin signalling pathway is also linked to cell cycle regulation [28] and has a crucial role in the over expression of cyclin B1, C and D in the development of HCC [29, 30]. Furthermore, the Wnt/ β -catenin signalling pathway interacts with other pathways that are deregulated in HCC including the Ras/ERK, PI3K/Akt/mTOR, and the IN/IRS1/IGF pathways (Fig. 1) [6]. These observations are significant in light of the previous reports showing that HBV infection is accompanied by the over expression of both cyclins B1 and D, the upregulation of PI3K/Akt and the inactivation of GSK3 β [8–10] and the Wnt/ β -catenin signalling pathway as a central component of HBV associated cell signalling events [6].

With the important role of Wnt/FZD/ β -catenin signalling in the development of HCC, and other cancers, intense research efforts have been directed to developing new compounds to inhibit this pathway [26]. Inhibitors of the Wnt/FZD/ β -catenin pathway (such as CGP049090, PKF115–584 and PKF118–310) have been shown to inhibit tumour growth in a number of HCC cell lines in culture [31]. These compounds in combination with other effective molecules result in a significant improvement in survival of patients with HCC [3]. A critical question to address is the role these treatment combinations have in patients with HBV associated HCC and their effect on HBV replication in hepatocytes.

PI3K/AKT and Ras/ERK1/2 pathways

Infection of hepatocytes with HBV is associated with the upregulation of PI3K/AKT and Ras/ERK1/2 [8–10] (Fig. 1). The consequences of this are a myriad of interrelated downstream effects that alter cell proliferation, cell cycle, apoptosis and ultimately contribute to oncogenic transformation. The up-regulation of both PI3K/AKT and Ras/ERK1/2 signalling pathways have been shown in both pre-neoplastic liver foci and in HCC's [32]. The activity of these kinases is closely related to the regulation of p21^{cip1}, which is increased in HBV infection of hepatocytes and contributes to G2 cell cycle arrest [8–10].

The PI3K/AKT pathway has a pivotal role in cell proliferation and the up-regulation of AKT results in the over-expression of cyclin D1, which has also been linked to HCC development [30]. Once activated AKT phosphorylates and inhibits GSK3 β and enhances cell survival and proliferation, activates c-Myc and NF κ B [8–10, 33, 34]. Inactivation of GSK3 β is central to several signalling pathways and leads to the subsequent degradation of cyclin D1, c-Myc and β -catenin thereby contributing to the over expression of these proteins and to HCC development [18, 24]. The Ras-ERK signalling pathway also plays a central role in regulating the growth and survival of cells [34], is activated by HBV and is intricately linked with the cell cycle machinery through the activation of cyclin D1 [8,

34]. The changes that occur within these pathways as a consequence of HBV infections are closely interrelated to regulate a fine balance that ultimately determines cell proliferation, viral replication, cell survival or death and ultimately oncogenic transformation.

The PI3K/AKT pathway also has a pivotal role in cell proliferation and the up-regulation of AKT results in the over-expression of cyclin D1, which has also been linked to HCC development [35]. A coordinated upregulation of both AKT and ERK is required for optimal activation of cyclin D1 [33, 36]. Once activated AKT enhances cell survival and proliferation, activates c-Myc and NF κ B [33, 36] and has the important role of inhibiting GSK3 β [34, 37]. Inactivation of GSK3 β by pAKT prevents the phosphorylation and subsequent degradation of cyclin D1 and c-Myc and thereby contributes to the over expression of these proteins.

The Ras-ERK signalling pathway also plays a central role in regulating the growth and survival of cells [34] and is intricately linked with the cell cycle machinery through the activation of cyclin D1 and the cyclin dependent kinases CDK4 and 6 together with the activation of cyclin E/CDK2 and c-Myc [34]. In addition, pERK activates JAK/STAT signalling resulting in the up-regulation of STAT3, which has been linked to oncogenic transformation [38].

Finally, the upregulation of c-Myc protein by HBV [8] would also be expected to contribute to HBV oncogenesis [33, 36] as this factor has an important role in concomitantly inducing both cell proliferation and apoptosis (in a p53 dependent manner) as a mechanism to protect against the selection of proliferative cellular lesions that might result in unrestrained cell growth.

The changes that occur within these pathways as a consequence of HBV infection are not isolated events but closely interrelated to regulate a fine balance that ultimately determines cell proliferation, viral replication and cell survival or death. It is these many and varied effects that determine cell fate and also place the PI3K/AKT pathway at the centre of the mechanisms that underlie HBV associated hepatocarcinogenesis.

HBV, hepatocyte apoptosis and HCC

Hepatocytes are particularly susceptible to Fas Ligand (FasL) induced apoptosis [39]. FasL is a member of the tumour necrosis factor (TNF) superfamily playing well-defined roles in the regulation of the immune system, embryonic development and tissue homeostasis. During acute HBV infection, liver-infiltrating lymphocytes will expose hepatocytes to FasL and induce widespread cell death [40]. While mature hepatocytes are highly sensitive to FasL, they are resistant to other death ligands such as TNF or TRAIL [41]. However, upon HBV infection, hepatocytes also become susceptible to these death

ligands [42]. This sensitisation to death stimuli may be an important contributor to the extensive liver destruction that can follow hepatitis B infection. It has been shown that replicating HBV causes hepatocyte apoptosis [43–46]. Interestingly, reports using transgenic mice containing the whole HBV genome have shown that enhanced hepatocarcinogenesis is associated with increased apoptosis and compensatory regeneration [47, 48].

Human data show that HBV infected patients, particularly those with detectable serum HBV surface antigen (HBsAg), are at increased risk of HBV reactivation when treated with TNF antagonists. Hepatocyte apoptosis mediated by TNF is an important mechanism by which HBV infected cells are eliminated from the liver. Therefore, therapeutics that augment the mechanisms through which TNF constrains HBV could be of great benefit to patients with chronic HBV infection. Cellular inhibitor of apoptosis proteins (cIAPs) regulate TNF signalling by promoting NF- κ B activation downstream of TNF receptor 1 (TNFR1) ligation, and this activation, in turn, promotes cell survival by antagonizing TNF mediated cell death. By attenuating TNF signalling during hepatitis B infection, cIAPs thereby restrict hepatocyte death and allow viral persistence. However, when the function of cIAPs is antagonized, TNF-mediated ligation of TNFR1 causes cell death. Mice deficient in cIAPs in the liver have an enhanced clearance of HBV infection [46]. This major finding raises the possibility of targeting IAPs to promote HBV clearance in patients. By inhibiting cIAPs with SMAC mimetics HBV can be eliminated from infected livers [45]. This provides an important therapeutic approach for the treatment of chronic hepatitis B and of HBV associated HCC. It is possible that combination therapy with inhibitors of the Ras/ERK, PI3K/AKT/mTOR and Wnt/ β -catenin together with SMAC mimetics could result in an enhanced anti-tumour effect and increased viral clearance [45].

HBV, cell cycle and HCC

The cellular mechanism underlying the development of hepatocellular carcinoma in HBV infected patients is likely to be multifactorial. An initiating oncogenic stimulus, which results in a number of changes within cell signalling pathways and cell cycle regulation, is tightly linked with an inflammatory and cytokine reaction driven by Kupffer cells in response to degradation products of apoptotic cells, chemical carcinogens and viral antigens [5, 13–15].

Like many DNA viruses, HBV manipulates the cell cycle machinery so that it can replicate more efficiently. Two important components of cell cycle regulation that are affected by HBV include a member of the kinase inhibitor protein family, p21^{cip1} [8–10, 49–52], which mediates cell cycle arrest at the G1/S and G2/M boundaries



of cell cycle by both p53-dependent [49, 51] and independent [50, 52] mechanisms and the Wnt/ β -catenin pathway [27]. Activation of ERK has been proposed to underlie the intranuclear accumulation of p21^{cip1} in G2 which appears to serve an important role in delaying cell cycle progression to mitosis in order to protect cells against DNA damaging agents and apoptosis [50, 52]. HBV infection of hepatocytes is associated with the activation of ERK and the subsequent up-regulation of p21^{cip1} thereby producing G2 cell cycle arrest [8–10]. This arrest serves a beneficial role for the virus because viral replication is increased in both G1 and G2 phases of cell cycle [53]. These studies serve to further reinforce the importance of elucidating the relationship between HBV and p21^{cip1} and apoptotic responses in hepatocytes.

The Wnt/ β -catenin pathway has also been shown to regulate G2 cell cycle arrest [54]. Cell cycle arrest may be beneficial for HBV because it results in enhanced viral replication in both G1 and G2 phases of cell cycle. The reliance of HBV on cell cycle and signalling events means that modulation of these cellular events with small molecules could result in viral clearance. HBV modulates the regulation of cellular transcription to promote cell proliferation, cell growth, cell survival and cell metabolism, [11, 55, 56]. Furthermore, HBV has been shown to promote HCC development by modulating the Wnt/ β -catenin pathway [57]. It has also been demonstrated that HBV, through the inhibition of the Smc5/6 complex, is a critical regulator of cellular chromatin and this may thereby regulate HBV cccDNA transcriptional activity [58]. The role of Wnt/ β -catenin signalling on the Smc5/6 complex and HBV cccDNA transcriptional activity has not yet been determined and warrants further investigation.

Limitations in the study of HBV associated HCC: benefits of liver organoids

Although HBV is a known hepatocarcinogen, the precise mechanism by which it causes HCC is unknown. An important obstacle to the study of molecular mechanisms underlying HBV associated HCC development has been the lack of in vitro (Fig. 4) and in vivo (Fig. 5) model systems that support human HBV infection. This is primarily because HBV is a hepatotropic virus that only infects human hepatocytes.

HCC is a complex multistage and multifactorial disease. The molecular pathogenesis and host-viral interactions that drive tumourigenesis remain elusive. One of the main challenges is the lack of satisfactory model systems to elucidate the underlying mechanisms. At the same time, there are major unmet needs for tumour characterisation and personalised therapeutic strategies to target driver mutations for better treatment outcome. A wide range of infection models have been used to address these unmet needs.



Fresh human primary hepatocytes

A lack of suitable human liver models for both HBV and HCV has hampered research in to the pathogenesis and developing a cure for HBV and vaccine development for HCV. Although the best source of primary human hepatocytes is fresh resected liver [59, 60] these cells are prone to de-differentiation, gradually losing their hepatic functionality [61]. This reduces the infectivity of primary hepatocytes by hepatitis viruses [62, 63]. In addition, these cells appear to have a limited lifespan and replicate poorly in 2D cultures (1 week) and sandwich cultures (2 weeks) [64–66] (Fig. 4).

Immortalized human cell lines

Immortalized continuous liver cancer derived cell lines have been the preferred model system to overcome the limitations of accessing primary human hepatocytes. These cell lines have been crucial to date for both research for pharmacological drug screening and validation (Fig. 4). The main strengths of continuous cell lines include ease of genetic manipulation, rapid expansion at comparatively low maintenance costs and thorough characterisation. However, it is well-known that continuous cell lines cultured in vitro are prone to genetic drift [67], or displaying phenotypic variation [66, 68, 69]. This could partially explain why there is no correlation between genetic expression patterns for multi-drug resistance observed when cell lines were compared to clinical primary cultures [70]. Interestingly, immortal cell lines, even though derived from different cancer types, are more likely to resemble each other rather than the clinical samples they were supposed to model [70–72]. Most of the routinely used liver cancer cell lines e.g. Huh7 and HepG2 not only show different morphology between laboratories but also a down-regulation of mature hepatocyte markers such as albumin or cytochrome P450 (CYP) family. Furthermore, none of the cell lines support natural HBV infection, probably due to the lack of mature hepatocyte receptors necessary for viral entry. Recently, sodium taurocholate cotransporting polypeptide (NTCP) was described as a putative receptor required for HBV entry and infection [73]. Since then, many attempts to introduce the NTCP transgene into hepatoma cell lines were made but, unlike natural infection, resulted in low levels of infection [73] and poor viral spreading [74]. In addition, while the expression of human NTCP confers susceptibility to HBV infection, continuous cell lines such as Huh7, HepG2 and HepaRG show a broad range of differences in susceptibility for HBV [75] as well as viral DNA integration [76]. This evidence suggests that HBV infectivity is not only determined by the binding receptor, but also through subsequent post-binding events or cell surface receptors in addition to NTCP. Recently, a newly developed hepatoma cell line named HLCZ01 that supports HBV infection by patient sera has

been described [77], opening a new promising prospect for HBV research.

Attempts have also been made to create immortal continuous human hepatocyte cell lines using viral oncogenes to bypass growth arrest of cultured adult hepatocytes, such as transduction of the simian virus 40 *T antigen* (SV40 Tag) or human papillomavirus 16 *E6/E7* genes [78–82]. Human hepatocytes are also known to possess limited in vitro proliferative capacity due to the restriction in their telomerase activity. Therefore, they are prone to replicative senescence [83, 84]. This problem can be overcome by transfecting *hTERT* retrovirus or Cre-loxP with the tet-on and -off system [81, 85]. However, immortalisation using *hTERT* is only suitable for a small subset of human hepatic cells, including foetal and neonatal hepatocytes, with mixed results [86–88].

Induced-pluripotent stem cell-derived hepatocytes

Since the discovery of “Yamanaka” factors (Oct3/4, Sox2, Klf4, and c-Myc) [89], there has been huge interest in induced-pluripotent stem (iPS) cell technology. Apart from avoiding ethical issues in working with stem cells, iPS cells bring a far-reaching promising impact for biomedical research, especially for tissue engineering, personalised medicine, disease modelling, and transplantation research (Fig. 4). One of the advantages of iPS cells is their ability to generate pluripotent stem cells from any cell source and can differentiate into any cell type. However, iPS cells possess a number of limitations [90]. iPS technology relies on using retrovirus or lentivirus for effective delivery of “Yamanaka” factors into somatic cells, hence posing the grave risk of unwanted activation of oncogenes or disrupting coding sequences of certain regulatory genes due to the random integration of viral vector into host transformed cell genome. Moreover, there is a high risk of ectopic expression of exogenous Oct3/4, Sox2, Klf4, and c-Myc genes inside iPS cells [91] that renders the cell lines unsuitable for transplantation due to high risk of neoplastic transformation. In fact, expression of this set of genes was found to be associated with tumourigenesis in a clinical setting [92]. Also, overexpression of Oct4 alone can cause epithelial cell dysplasia in mice [93], ectopic expression of Sox2 is associated with mucinous colon carcinomas [94], while Klf4 is linked to breast cancer [95]. C-Myc is itself found to be overexpressed in more than 70% of cancers [96]. Indeed, in iPS cells, c-Myc reactivation was often found to be associated with tumour development [97, 98].

Many alternative technologies have been developed to address these safety concerns. On one hand, mouse iPS cells were generated free from viral vectors through repeated transfection of expression plasmids containing cDNAs for the “Yamanaka” factors [97]. On the other

hand, there have been many attempts to limit the use of c-Myc in mouse and human fibroblasts [99, 100]. With respect to modelling functional liver tissue, iPS cells can generate liver buds and be successfully implanted to rescue liver failure in mice [101]. However, the majority of iPS cell-derived human hepatocytes are still inferior to primary hepatocytes isolated from resected liver. Rather, iPS-derived hepatocytes mimicked foetal hepatocytes [102–104]. One reason for a lack of adult features may be due to the appropriate stoichiometry of reprogramming factors as well as the origin of the transformed cells required for proper reprogramming. Additionally, for iPS cells to be fully differentiated into mature hepatocytes, suitable epigenetic modifications must occur [105], as some human iPS cells tend to retain residual somatic epigenetic markers, leading to certain DNA methylation profiles [106]. For instance, a recent study showed that the CYP enzyme promoter in embryonic stem cell-derived hepatocytes is highly hypermethylated, leading to an inferior CYP profile compared to primary hepatocytes [107]. Experimentally, inhibition of DNA methyltransferases and histone deacetylases in this cell line can rescue this phenotype, but this is a real limitation for application in a clinical setting.

In addition, differentiation of iPS-derived hepatocytes also depends heavily on the induction cocktail [108] as well as stromal, endothelial [109, 110], fibroblast [111], and hepatic resident cells that help ameliorate the differentiation efficiency [101]. In fact, even primary hepatocytes co-cultured in a specific pattern with stromal cells to better mimic the *in vivo* situation illustrated higher NTCP expression and supported better HBV infection [112]. Recent studies show that NTCP expression in differentiated iPS cells can achieve a level close to primary hepatocytes; however, the infection efficiency is still very modest [113, 114]. In addition, efficient viral infection required a very high multiplicity of infection (MOI). An MOI of 50 gave 30% HBV-positive cells while an MOI of 200 yielded 60% infected cells and MOI of 1000 resulted in infection of almost every cell [115]. Another study using iPS-derived hepatocytes grown in a 3D culture system also showed a similar result [116]. This strongly suggests that the HBV infection may require additional elements besides NTCP.

In vivo animal models

Among animals available for HBV research, the chimpanzee is the only model that can be infected naturally by patient sera and develop chronic infection closely mimicking human conditions (Fig. 5). However, due to substantial ethical concerns, the use of chimpanzees for HBV research is heavily restricted. Other primate models, such as gibbons or macaques, can be infected with HBV; however, they showed only a mild acute

hepatitis. Hence, alternative animal models such as woodchuck or duck have been used to study hepadnavirus virology, as the respective infectious agents are evolutionarily related to human HBV. Yet, these animal hepatitis viruses still differ extensively from HBV. Recently, a macaque species named *Macaca fascicularis* from Mauritius Island [117] was found to support natural HBV infection and develop chronic infection. However, a number of ethical issues working with these primates still exist.

For non-primate animals, HBV can only infect tree shrew tupaia [118]. Many attempts were made to develop a mouse model that is susceptible to HBV infection. In fact, transgenic mouse models, although not entirely mimicking the scenario of HBV infection in humans, have provided some meaningful data for better understanding of the replication and life cycle of HBV. Also, mice expressing human NTCP fail to support natural HBV infection, but support hepatitis D virus which exploits HBV surface proteins to initiate infection [75]. In particular, it was shown that HBV could gain entry into human NTCP-expressing mouse hepatocytes, but failed to carry out viral transcription [119] due to the lack of a host cell dependency factor [120]. Other approaches include using human liver transplantation into mice to develop chimeric humanised mouse models (reviewed in [121]) which are susceptible to natural HBV infection. However, the process is very complicated and expensive.

A full-length HBV genome transgenic mouse has also been shown to produce complete infectious HBV particles [122]. However, because these mice are immune-tolerant to HBV, they do not show histological changes in the liver consistent with hepatitis. Similar approaches to create transgenic mice expressing HBV structural proteins were also carried out for surface proteins [123], precore and core [124], and HBx [125]. Among these studies, only HBx transgenic mice developed HCC. However, later studies disputed this claim, referring to the functional role of HBx only as a potential oncogenic agent [126, 127].

Although HBV transgenic mouse models are very valuable, they are not very useful to investigate host-pathogen interactions, especially with respect to the immunological response and viral clearance. That is not to mention the labour, cost, and time to generate and validate the models. In fact, the most efficient mouse model for studying the immunopathogenesis of HBV infection makes use of hydrodynamic tail-vein injection to introduce HBV into mice. This technique results in a high efficiency of transfection of hepatocytes [128, 129]. Hence, the *in vitro* studies of HBV proteins could be translated into *in vivo* models easily. The main benefit of this technique over *in vitro* models is for studying the immune response in

scenarios of acute infection as well as host-pathogen interaction of HBV proteins [130].

Recently, it was shown that complementation of primary hepatocytes isolated from cynomolgus macaques, rhesus macaques, and pigs with human NTCP by adenoviral transduction resulted in fully susceptible HBV infection comparable to human hepatocytes [131]. However, like mouse models, the process to create human-NTCP transgenic animals from these species for *in vivo* studies is very complicated and expensive and introduces additional ethical issues in working with these animals.

Liver organoid derived from adult hepatic stem cells

Recently, Huch and colleagues [132, 133] showed that leucine rich repeat containing G protein-coupled receptor 5 (LGR5) expressing cells isolated from liver tissue can give rise to 3-dimensional *ex vivo* mini-liver structures, referred to as liver organoids (Fig. 4). These liver organoids not only retain the characteristics of their original tissue, they are also able to undergo unlimited expansion and can be differentiated into mature hepatocyte-like cells that can rescue a liver-defective mouse model [132]. Thus, this provides a very valuable cell source for disease modelling, toxicology testing, as well as transplantation research and for personalised medicine.

Compared to iPS-derived hepatocytes, the adult stem-cell-derived liver organoid model possesses many advantages. Firstly, liver organoid cells have been shown to have a stable genome and very low risk of spontaneous mutation or chromosomal alteration [133]. Secondly, as they originate from liver tissue, they are not subjected to unexpected hypermethylation of liver-specific markers or functional proteins, which is common in iPS generated organoids. In addition, the hepatic stem cells that give rise to liver organoids are relatively tough and resilient. Primary tissues stored in cold medium for 3 days, or frozen in DMSO or snap-frozen in liquid nitrogen can still yield organoids [134]. The same properties have not been observed in iPS-derived liver cultures. Another advantage of liver organoids is the straightforward and robust protocol for isolating and expanding cells from donors' tissue. Established organoids can be cryopreserved and recovered, which is very important for tissue banking. One of the reasons for these advantages is due to the 3D Matrigel culture that allows hepatocyte polarisation as well as facilitating interactions between cell-cell and cell-microenvironment [135]. In fact, hepatic stem cells cultured on a 2D monolayer fail to maintain hepatic stemness [136] and the cellular chromosomes become unstable after long-term passage [137]. Adult tissue stem-cell-derived organoids in 3D culture helps bridge this gap [138]. HBV only infects mature human hepatocytes. Hence, the differentiated liver organoids are

susceptible to natural infection with HBV, producing high titre virus in the supernatant [139]. The first report of human liver organoid culture and characterisation was in 2015 [133], and this year, the first publication on HBV infection of these organoids [139]. Much has been learnt from iPS and the hepatoma HLCZ01, thus the development of a liver organoid model system susceptible for HBV infection was much easier.

While iPS cells and hepatoma cell lines stop short as a model system for researching HBV infection or drug assay for anti-viral capability, liver organoids offer far more scope. For example, HBV chronic-infected patients who are at high risk for developing cirrhosis or HCC, liver organoid technology can support the development of promising personalised medicine regimens including but not limited to: testing cirrhosis/tumour tissues for precise drug regimes, manufacture potential materials with high susceptibility for transplantation, or generate genome-edited *ex vivo* tissue free of defects or with boosted immunological response. This is especially important for HCC, where tumour tissues are extensively heterogeneous and only the liver organoid system can closely recapitulate this complexity. Thus, it is tremendously valuable for better diagnosis and treatment. In fact, many translational applications along these lines have been carried out for pancreatic [140] and colorectal cancer [141]. None of this can be achieved using iPS cells, *in vivo* mouse models or immortal cell lines (Figs. 4 and 5).

Conclusions

The organoid revolution led by the Clevers laboratory has made personalised medicine a tangible reality for solid tumours of the colon, breast and pancreas. Using high throughput screening, tumour cell responses can be tested to drugs in isolation and in combination. Our ability to now grow HCC tumours in tissue culture as patient-derived tumour organoids means we can do the same for liver cancer patients. Furthermore, organoid technology has led to a better understanding of the molecular mechanisms of how a normal colon epithelial cell becomes a cancer cell. We are on the cusp of extending this understanding to liver cancer to curtail the alarming trend in mortality.

On the other hand, organoids established from normal human tissues are proving to be invaluable models of natural infection, particularly for pathogens that only infect human cells. Normal liver organoids were first established, again by the Clevers laboratory, in 2013 [132], and the further improvements reported recently by the group [142] will no doubt advance our understanding of the oncogenic interplay between HBV infection and cellular signalling pathways.

Abbreviations

3D: 3 dimensional; AIDS: Acquired Immune Deficiency Syndrome; APC: Adenomatous polyposis coli; cIAPs: cellular inhibitor of apoptosis proteins; CK1: Casein kinase 1; CYP: Cytochrome P450; DKK: Dickkopf; DMSO: Dimethyl sulphoxide; FasL: Fas Ligand; FZD: Frizzled; GSK3 β : Glycogen synthase kinase3- β ; HBsAg: HBV surface antigen; HBV: Hepatitis B Virus; HBx: HBV X protein; HCC: Hepatocellular Carcinoma; HIV: Human Immunodeficiency Virus; IGF: Insulin-like growth factor 1; iPS: induced-pluripotent stem; IRS1: Insulin receptor substrate 1; JNK: c-Jun N-terminal kinase; LEF: Lymphoid enhancer-binding factor; LGR5: Leucine rich repeat containing G protein-coupled receptor 5; LRP: Low-density lipoprotein receptor-related protein; MAPK: Mitogen-activated protein kinases; MOI: Multiplicity of infection; mTOR: mammalian target of rapamycin; NTCP: Sodium taurocholate cotransporting polypeptide; PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase; sFRP: secreted FZD-related protein; SOCS3: Suppressor of cytokine signalling 3; TCF: T-cell-specific transcription factor; TNF: Tumour necrosis factor; TNFR1: TNF receptor 1; WIF: Wnt inhibitory factor; β -trcp: β -transducin repeat-containing protein

Acknowledgements

The authors wish to thank Gavan Mitchell for helping generate the figures in this manuscript.

Authors' contributions

JT, BMT, DC, LES, RHMS and EV contributed equally to writing the review. All authors read and approved the final manuscript.

Funding

Funding is gratefully acknowledged from the following; National Health and Medical Research Council of Australia (NHMRC) project grants (566679 and APP1099302) and Melbourne Health project grants (605030 and PG-002) awarded to EV. JT is supported by an NHMRC Practitioner Fellowship, number 106043. Funding bodies did not fund this review specifically but supported the research in our laboratories that led to some of our conclusions.

Availability of data and materials

Not applicable. We do not include any data.

Ethics approval and consent to participate

Not applicable as it is a review – but ethics approval for studies leading to conclusions in this review were from the University of Melbourne human and animal ethics committees.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3010, Australia. ²The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3010, Australia. ³Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria 3010, Australia. ⁴School of Pharmacy and Biomedical Sciences, Curtin University, Perth, WA 6845, Australia.

Received: 23 February 2019 Accepted: 9 July 2019

Published online: 18 July 2019

References

- MacLachlan JH, Locarnini S, Cowie BC. Estimating the global prevalence of hepatitis B. *Lancet*. 2015;386(10003):1515–7.
- Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. *Lancet*. 2017;390:1151–210.
- Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. *Hepatology*. 2008;48:1312–27.
- Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. *Anticancer Res*. 2010;30:4951–8.
- Karin M. The I κ B kinase - a bridge between inflammation and cancer. *Cell Res*. 2008;18:334–42.
- Chung W, Kim M, de la Monte S, Longato L, Carlson R, Slagle BL, Dong X, Wands JR. Activation of signal transduction pathways during hepatic oncogenesis. *Cancer Lett*. 2016;370:1–9.
- Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. *Hepatology*. 2013;57:399–408.
- Chin R, Earnest-Silveira L, Koeberlein B, Franz S, Zentgraf H, Dong X, Gowans E, Bock CT, Torresi J. Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. *J Hepatol*. 2007;47:325–37.
- Chin R, Earnest-Silveira L, Koeberlein B, Franz S, Zentgraf H, Bowden S, Bock CT, Torresi J. Failure of lamivudine to reverse hepatitis B virus-associated changes in ERK, Akt and cell cycle regulatory proteins. *Antivir Ther*. 2008;13:221–30.
- Chin R, Nachbur U, Earnest-Silveira L, Bankovacki A, Koeberlein B, Zentgraf H, Bock CT, Silke J, Torresi J. Dysregulation of hepatocyte cell cycle and cell viability by hepatitis B virus. *Virus Res*. 2010;147:7–16.
- Bock C-T, Toan NL, Koeberlein B, Song LH, Chin R, Kremsner PG, Zentgraf H, Kandolf R, Torresi J. Subcellular mislocalization of mutant hepatitis B X-proteins in hepatocellular carcinoma: dysregulation of STAT/SOCS signalling. *Intervirology*. 2008;51:432–43.
- Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. *Carcinogenesis*. 2004;25:2023–32.
- Dong Z, Wei H, Sun R, Tian Z. The roles of innate immune cells in liver injury and regeneration. *Cell Mol Immunol*. 2007;4:241–52.
- Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. *Liver Int*. 2006;26:1175–86.
- Karin M, Greten FR. NF- κ B: linking inflammation and immunity to cancer development and progression. *Nat Rev Immunol*. 2005;5:749–59.
- Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio P, Rizzetto M, Craxi A. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. *Hepatology*. 2004;40:883–91.
- Vincan E, Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. *Clin Exp Metastasis*. 2008;25:657–63.
- Clevers H, Nusse R. Wnt/ β -catenin signaling and disease. *Cell*. 2012;149:1192–205.
- Wiese KE, Nusse R, van Amerongen R. Wnt signalling: conquering complexity. *Development*. 2018;145:dev165902.
- Humphries AC, Mlodzik M. From instruction to output: Wnt/PCP signaling in development and cancer. *Curr Opin Cell Biol*. 2018;51:110–6.
- McNeill H, Woodgett JR. When pathways collide: collaboration and crosstalk among signalling proteins in development. *Nat Rev Mol Cell Biol*. 2010;11:404–13.
- Ding Y, Dale T. Wnt signal transduction: kinase cogs in a nano-machine? *Trends Biochem Sci*. 2002;27:327–9.
- Pheesse T, Flanagan D, Vincan E. Frizzled7: a promising Achilles' heel for targeting the Wnt receptor complex to treat Cancer. *Cancers (Basel)*. 2016; 8(5). <https://doi.org/10.3390/cancers8050050>.
- Nejak-Bowen KN, Monga SP. β -catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. *Semin Cancer Biol*. 2011;21:44–58.
- Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P, Wands JR. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/ β -catenin signaling pathway in hepatocellular carcinoma cells. *J Hepatol*. 2008;48:780–91.
- Vilchez V, Turcios L, Marti F, Gedaly R. Targeting Wnt/ β -catenin pathway in hepatocellular carcinoma treatment. *World J Gastroenterol*. 2016;22:823–32.
- Kim SS, Cho HJ, Lee HY, Park JH, Noh CK, Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW, Cheong JY. Genetic polymorphisms in the Wnt/ β -catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma. *Clin Biochem*. 2016;49:792–801.

28. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. *Proc Natl Acad Sci U S A*. 1999;96:5522–7.
29. Wang B, Xunsun, Liu JY, Yang D, Yang LL, Kong DX, Meng XW. The effect of cell cycle and expression of cyclin B1 and cyclin C protein in hepatocellular carcinoma cell line HepG2 and SMMC-7721 after of silencing beta-catenin gene. *Hepatogastroenterology*. 2012;59:515–8.
30. Gotoh J, Obata M, Yoshie M, Kasai S, Ogawa K. Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. *Carcinogenesis*. 2003;24:435–42.
31. Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. *Int J Cancer*. 2010;126:2426–36.
32. Evert M, Sun J, Pichler S, Slavova N, Schneider-Stock R, Dombrowski F. Insulin receptor, insulin receptor substrate-1, Raf-1, and Mek-1 during hormonal hepatocarcinogenesis by intrahepatic pancreatic islet transplantation in diabetic rats. *Cancer Res*. 2004;64:8093–100.
33. Arsuru M, Cavin LG. Nuclear factor-kappaB and liver carcinogenesis. *Cancer Lett*. 2005;229:157–69.
34. Massague J. G1 cell-cycle control and cancer. *Nature*. 2004;432:298–306.
35. Deane NG, Parker MA, Aramandla R, Diehl L, Lee WJ, Washington MK, Nanney LB, Shyr Y, Beauchamp RD. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. *Cancer Res*. 2001;61:5389–95.
36. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. *J Biol Chem*. 2002;277:11617–20.
37. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature*. 2001;414:799–806.
38. Zhao L, Hart S, Cheng J, Melenhorst JJ, Bierie B, Ernst M, Stewart C, Schaper F, Heinrich PC, Ullrich A, et al. Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK. *J Biol Chem*. 2004;279:44093–100.
39. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. *Nat Med*. 1993;364(6440):806–9.
40. Jin Y, Fuller L, Carreno M, Zucker K, Roth D, Esquenazi V, Karatzas T, Swanson SJ, Tzakis AG, Miller J. The immune reactivity role of HCV-induced liver infiltrating lymphocytes in hepatocellular damage. *J Clin Immunol*. 1997;17:140–53.
41. Liang X, Du JF, Liu Y, Cui M, Ma C, Han L, Qu Z, Zhang Z, Sun Z, Zhang L, et al. The hepatitis B virus protein MHBs(t) sensitizes hepatoma cells to TRAIL-induced apoptosis through ERK2. *Apoptosis*. 2007;12:1827–36.
42. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. *Proc Natl Acad Sci U S A*. 1997;94:8744–9.
43. Lee AT, Ren J, Wong ET, Ban KH, Lee LA, Lee CG. The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage. *J Biol Chem*. 2005;280:33525–35.
44. Chan JF, To KK, Tse H, Lau CC, Li IW, Hung IF, Chan KH, Cheng VC, Lai TS, Woo PC, et al. The lower serum immunoglobulin G2 level in severe cases than in mild cases of pandemic H1N1 2009 influenza is associated with cytokine dysregulation. *Clin Vaccine Immunol*. 2011;18:305–10.
45. Ebert G, Allison C, Preston S, Cooney J, Toe JG, Stutz MD, Ojaimi S, Baschuk N, Nachbur U, Torresi J, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis. *Proc Natl Acad Sci U S A*. 2015;112:5803–8.
46. Ebert G, Preston S, Allison C, Cooney J, Toe JG, Stutz MD, Ojaimi S, Scott HW, Baschuk N, Nachbur U, et al. Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. *Proc Natl Acad Sci U S A*. 2015;112:5797–802.
47. Zheng Y, Chen WL, Louie SG, Yen TS, Ou JH. Hepatitis B virus promotes hepatocarcinogenesis in transgenic mice. *Hepatology*. 2007;45:16–21.
48. Baumert TF, Yang C, Schurmann P, Kock J, Ziegler C, Grulich C, Nassal M, Liang TJ, Blum HE, von Weizsacker F. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. *Hepatology*. 2005;41:247–56.
49. Bates S, Ryan KM, Phillips AC, Vousden KH. Cell cycle arrest and DNA endoreduplication following p21Waf1/Cip1 expression. *Oncogene*. 1998;17:1691–703.
50. Niculescu AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing Endoreduplication. *Mol Cell Biol*. 1998;18:629–43.
51. Dulic V, Stein GH, Farahi Far D, Reed SI. Nuclear Accumulation of p21Cip1 at the Onset of a Role at the G2/M-Phase Transition. *Mol Cell Biol*. 1998;18:546–57.
52. Dangi S, Chen FM, Shapiro P. Activation of extracellular signal-regulated kinase (ERK) in G2 phase delays mitotic entry through p21cip1. *Cell Prolif*. 2006;39:261–79.
53. Ozer A, Khaoustov VI, Mearns M, Lewis DE, Genta RM, Darlington GJ, Yoffe B. Effect of hepatocyte proliferation and cellular DNA synthesis on hepatitis B virus replication. *Gastroenterology*. 1996;110:1519–28.
54. Koch S, Acebron SP, Herbst J, Hatiboglu G, Niehrs C. Post-transcriptional Wnt signaling governs Epididymal sperm maturation. *Cell*. 2015;163:1225–36.
55. Han HJ, Jung EY, Lee WJ, Jang KL. Cooperative repression of cyclin-dependent kinase inhibitor p21 gene expression by hepatitis B virus X protein and hepatitis C virus core protein. *FEBS Lett*. 2002;518:169–72.
56. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. *J Virol*. 2004;78:12725–34.
57. Chen Z, Tang J, Cai X, Huang Y, Gao Q, Liang L, Tian L, Yang Y, Zheng Y, Hu Y, Tang N. HBx mutations promote hepatoma cell migration through the Wnt/beta-catenin signaling pathway. *Cancer Sci*. 2016;107(10):1380–9.
58. Decorsiere A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, Livingston CM, Niu C, Fletcher SP, Hantz O, Strubin M. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. *Nature*. 2016;531:386–9.
59. Bhogal RH, Hodson J, Bartlett DC, Weston CJ, Curbishley SM, Haughton E, Williams KT, Reynolds GM, Newsome PN, Adams DH, Afford SC. Isolation of primary human hepatocytes from normal and diseased liver tissue: a one hundred liver experience. *PLoS One*. 2011;6:e18222.
60. Vondran FW, Katenz E, Schwartlander R, Morgul MH, Raschok N, Gong X, Cheng X, Kehr D, Sauer IM. Isolation of primary human hepatocytes after partial hepatectomy: criteria for identification of the most promising liver specimen. *Artif Organs*. 2008;32:205–13.
61. Dash A, Simmers MB, Deering TG, Berry DJ, Feaver RE, Hastings NE, Pruett TL, LeCluyse EL, Blackman BR, Wamhoff BR. Hemodynamic flow improves rat hepatocyte morphology, function, and metabolic activity in vitro. *Am J Physiol Cell Physiol*. 2013;304:C1053–63.
62. Gripon P, Diot C, Theze N, Fourel I, Loreal O, Brechot C, Guguen-Guillouzo C. Hepatitis B virus infection of adult human hepatocytes cultured in the presence of dimethyl sulfoxide. *J Virol*. 1988;62:4136–43.
63. Galle PR, Hagelestein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H. In vitro experimental infection of primary human hepatocytes with hepatitis B virus. *Gastroenterology*. 1994;106:664–73.
64. Genove E, Schmitmeier S, Sala A, Borros S, Bader A, Griffith LG, Semino CE. Functionalized self-assembling peptide hydrogel enhance maintenance of hepatocyte activity in vitro. *J Cell Mol Med*. 2009;13:3387–97.
65. Xiao W, Perry G, Komori K, Sakai Y. New physiologically-relevant liver tissue model based on hierarchically cocultured primary rat hepatocytes with liver endothelial cells. *Integr Biol (Camb)*. 2015;7:1412–22.
66. Khazali AS, Clark AM, Wells A. A pathway to personalizing therapy for metastases using liver-on-a-Chip platforms. *Stem Cell Rev*. 2017;13:364–80.
67. Burdall SE, Hanby AM, Lansdown MR, Speirs V. Breast cancer cell lines: friend or foe? *Breast Cancer Res*. 2003;5:89–95.
68. Bahia H, Ashman JN, Cawkwell L, Lind M, Monson JR, Drew PJ, Greenman J. Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization. *Int J Oncol*. 2002;20:489–94.
69. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, Hwang MS, Darling DS, Coleman IM, Nelson PS, et al. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. *Am J Pathol*. 2011;179:400–10.
70. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. *Proc Natl Acad Sci U S A*. 2011;108:18708–13.
71. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. *Front Immunol*. 2014;5:614.
72. Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, et al. Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. *Hum Mol Genet*. 2001;10:1413–9.
73. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *Elife*. 2012;1:e00049.

74. Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, Gao Z, Jing Z, Song M, Xu G, et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. *J Virol*. 2013;87:7977–91.
75. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, Stindt J, Koniger C, Nassal M, Kubitz R, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. *Gastroenterology*. 2014;146:1070–83.
76. Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B virus DNA integration occurs early in the viral life cycle in an in vitro infection model via sodium taurocholate Cotransporting polypeptide-dependent uptake of enveloped virus particles. *J Virol*. 2018;92(11). <https://doi.org/10.1128/JVI.02007-17>.
77. Yang D, Zuo C, Wang X, Meng X, Xue B, Liu N, Yu R, Qin Y, Gao Y, Wang Q, et al. Complete replication of hepatitis B virus and hepatitis C virus in a newly developed hepatoma cell line. *Proc Natl Acad Sci U S A*. 2014;111: E1264–73.
78. Clayton RF, Rinaldi A, Kandyba EE, Edward M, Willberg C, Klenerman P, Patel AH. Liver cell lines for the study of hepatocyte functions and immunological response. *Liver Int*. 2005;25:389–402.
79. Fukaya K, Asahi S, Nagamori S, Sakaguchi M, Gao C, Miyazaki M, Namba M. Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT. *In Vitro Cell Dev Biol Anim*. 2001;37:266–9.
80. Pfeifer AM, Cole KE, Smoot DT, Weston A, Groopman JD, Shields PG, Vignaud JM, Juillerat M, Lipsky MM, Trump BF, et al. Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. *Proc Natl Acad Sci U S A*. 1993;90:5123–7.
81. Ramboer E, De Craene B, De Kock J, Vanhaecke T, Berx G, Rogiers V, Vinken M. Strategies for immortalization of primary hepatocytes. *J Hepatol*. 2014;61:925–43.
82. Ramboer E, Vanhaecke T, Rogiers V, Vinken M. Immortalized human hepatic cell lines for in vitro testing and research purposes. *Methods Mol Biol*. 2015; 1250:53–76.
83. Ozturk M, Arslan-Ergul A, Bagislar S, Senturk S, Yuzugullu H. Senescence and immortality in hepatocellular carcinoma. *Cancer Lett*. 2009;286:103–13.
84. Wege H, Le HT, Chui MS, Liu L, Wu J, Giri R, Malhi H, Sappal BS, Kumaran V, Gupta S, Zern MA. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. *Gastroenterology*. 2003;124:432–44.
85. Waki K, Anno K, Ono T, Ide T, Chayama K, Tahara H. Establishment of functional telomerase immortalized human hepatocytes and a hepatic stellate cell line for telomere-targeting anticancer drug development. *Cancer Sci*. 2010;101:1678–85.
86. Tsuruga Y, Kiyono T, Matsushita M, Takahashi T, Kasai H, Matsumoto S, Todo S. Establishment of immortalized human hepatocytes by introduction of HPV16 E6/E7 and hTERT as cell sources for liver cell-based therapy. *Cell Transplant*. 2008;17:1083–94.
87. Okitsu T, Kobayashi N, Jun HS, Shin S, Kim SJ, Han J, Kwon H, Sakaguchi M, Totsugawa T, Kohara M, et al. Transplantation of reversibly immortalized insulin-secreting human hepatocytes controls diabetes in pancreatectomized pigs. *Diabetes*. 2004;53:105–12.
88. Totsugawa T, Yong C, Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, Noguchi H, Okitsu T, Westerman KA, Kohara M, Reth M, et al. Survival of liver failure pigs by transplantation of reversibly immortalized human hepatocytes with tamoxifen-mediated self-recombination. *J Hepatol*. 2007; 47:74–82.
89. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*. 2006;126:663–76.
90. Medvedev SP, Shevchenko AI, Zakian SM. Induced pluripotent stem cells: problems and advantages when applying them in regenerative medicine. *Acta Nat*. 2010;2:18–28.
91. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. *Nature*. 2007;448:313–7.
92. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nat Genet*. 2008;40:499–507.
93. Hochdlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell*. 2005;121:465–77.
94. Cheng AC, Jacups SP, Ward L, Currie BJ. Melioidosis and aboriginal seasons in northern Australia. *Trans R Soc Trop Med Hyg*. 2008;102(Suppl 1):S26–9.
95. Ghaleb AM, Nandan MO, Chanchevalap S, Dalton WB, Hisamuddin IM, Yang VW. Kruppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. *Cell Res*. 2005;15:92–6.
96. Kuttler F, Mai S. c-Myc, genomic instability and disease. *Genome Dyn*. 2006; 1:171–90.
97. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. *Science*. 2008; 322:949–53.
98. Duinsbergen D, Salvatori D, Eriksson M, Mikkers H. Tumors originating from induced pluripotent stem cells and methods for their prevention. *Ann N Y Acad Sci*. 2009;1176:197–204.
99. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nat Biotechnol*. 2008;26:101–6.
100. Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct reprogramming of mouse fibroblasts. *Cell Stem Cell*. 2008;2:10–2.
101. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y, Zheng YW, Koike N, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. *Nature*. 2013;499:481–4.
102. Yu Y, Liu H, Ikeda Y, Amiot BP, Rinaldo P, Duncan SA, Nyberg SL. Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies. *Stem Cell Res*. 2012;9:196–207.
103. Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. Pluripotent stem cell-derived hepatocyte-like cells. *Biotechnol Adv*. 2014;32:504–13.
104. Gerbal-Chaloin S, Funakoshi N, Caillaud A, Gondeau C, Champon B, Si-Tayeb K. Human induced pluripotent stem cells in hepatology: beyond the proof of concept. *Am J Pathol*. 2014;184:332–47.
105. Takahashi K, Yamanaka S. A developmental framework for induced pluripotency. *Development*. 2015;142:3274–85.
106. Ohi Y, Qin H, Hong C, Blouin L, Polo JM, Guo T, Qi Z, Downey SL, Manos PD, Rossi DJ, et al. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. *Nat Cell Biol*. 2011;13:541–9.
107. Park HJ, Choi YJ, Kim JW, Chun HS, Im I, Yoon S, Han YM, Song CW, Kim H. Differences in the epigenetic regulation of cytochrome P450 genes between human embryonic stem cell-derived hepatocytes and primary hepatocytes. *PLoS One*. 2015;10:e0132992.
108. Shan J, Schwartz RE, Ross NT, Logan DJ, Thomas D, Duncan SA, North TE, Goessling W, Carpenter AE, Bhatia SN. Identification of small molecules for human hepatocyte expansion and iPSC differentiation. *Nat Chem Biol*. 2013;9:514–20.
109. Soto-Gutierrez A, Navarro-Alvarez N, Zhao D, Rivas-Carrillo JD, Lebkowski J, Tanaka N, Fox IJ, Kobayashi N. Differentiation of mouse embryonic stem cells to hepatocyte-like cells by co-culture with human liver nonparenchymal cell lines. *Nat Protoc*. 2007;2:347–56.
110. Asai A, Aihara E, Watson C, Mourya R, Mizuochi T, Shivakumar P, Phelan K, Mayhew C, Helmrath M, Takebe T, et al. Paracrine signals regulate human liver organoid maturation from induced pluripotent stem cells. *Development*. 2017;144:1056–64.
111. Berger DR, Ware BR, Davidson MD, Allsup SR, Khetani SR. Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro. *Hepatology*. 2015;61:1370–81.
112. Shlomai A, Schwartz RE, Ramanan V, Bhatia A, de Jong YP, Bhatia SN, Rice CM. Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems. *Proc Natl Acad Sci U S A*. 2014;111:12193–8.
113. Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M, Tsunoda T, Nitta S, Asano Y, Nagata H, Otani S, et al. Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus. *Sci Rep*. 2016;6:29358.
114. Sakurai F, Mitani S, Yamamoto T, Takayama K, Tachibana M, Watashi K, Wakita T, Iijima S, Tanaka Y, Mizuguchi H. Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection. *Sci Rep*. 2017;7:45698.
115. Xia Y, Carpentier A, Cheng X, Block PD, Zhao Y, Zhang Z, Protzer U, Liang TJ. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. *J Hepatol*. 2017; 66:494–503.
116. Nie YZ, Zheng YW, Miyakawa K, Murata S, Zhang RR, Sekine K, Ueno Y, Takebe T, Wakita T, Ryo A, Taniguchi H. Recapitulation of hepatitis B virus-

- host interactions in liver organoids from human induced pluripotent stem cells. *EBioMedicine*. 2018;35:114–23.
117. Dupinay T, Gheit T, Roques P, Cova L, Chevallier-Queyron P, Tasahsu SI, Le Grand R, Simon F, Cordier G, Wakrim L, et al. Discovery of naturally occurring transmissible chronic hepatitis B virus infection among *Macaca fascicularis* from Mauritius Island. *Hepatology*. 2013;58:1610–20.
 118. Walter E, Keist R, Niederost B, Pult I, Blum HE. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. *Hepatology*. 1996;24:1–5.
 119. Li H, Zhuang Q, Wang Y, Zhang T, Zhao J, Zhang Y, Zhang J, Lin Y, Yuan Q, Xia N, Han J. HBV life cycle is restricted in mouse hepatocytes expressing human NTCP. *Cell Mol Immunol*. 2014;11:175–83.
 120. Lempp FA, Mutz P, Lipps C, Wirth D, Bartenschlager R, Urban S. Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor. *J Hepatol*. 2016;64:556–64.
 121. Allweiss L, Dandri M. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. *J Hepatol*. 2016;64:517–31.
 122. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. *J Virol*. 1995;69:6158–69.
 123. Chisari FV, Pinkert CA, Milich DR, Filippi P, McLachlan A, Palmiter RD, Brinster RL. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. *Science*. 1985;230:1157–60.
 124. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. *Hepatology*. 2003;38:1075–86.
 125. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. *Nature*. 1991;351:317–20.
 126. Slagle BL, Lee TH, Medina D, Finegold MJ, Butel JS. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. *Mol Carcinog*. 1996;15:261–9.
 127. Quetier I, Brezillon N, Revaud J, Ahodantin J, DaSilva L, Soussan P, Kremsdorf D. C-terminal-truncated hepatitis B virus X protein enhances the development of diethylnitrosamine-induced hepatocellular carcinogenesis. *J Gen Virol*. 2015;96:614–25.
 128. Preston SP, Pellegrini M, Ebert G. Hydrodynamic injection as a method of gene delivery in mice: a model of chronic hepatitis B virus infection. *Methods Mol Biol*. 2016;1419:109–15.
 129. Kim MJ, Ahituv N. The hydrodynamic tail vein assay as a tool for the study of liver promoters and enhancers. *Methods Mol Biol*. 2013;1015:279–89.
 130. Yang PL, Althage A, Chung J, Chisari FV. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. *Proc Natl Acad Sci U S A*. 2002;99:13825–30.
 131. Lempp FA, Wiedtke E, Qu B, Roques P, Chemin I, Vondran FWR, Le Grand R, Grimm D, Urban S. Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes. *Hepatology*. 2017;66:703–16.
 132. Huch M, Dorrell C, Boj SF, van Es JH, Li VS, van de Wetering M, Sato T, Hamer K, Sasaki N, Finegold MJ, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. *Nature*. 2013;494:247–50.
 133. Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, Ellis E, van Wenum M, Fuchs SA, de Ligt J, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. *Cell*. 2015;160:299–312.
 134. Nantasanti S, de Bruin A, Rothuizen J, Penning LC, Schotanus BA. Concise review: organoids are a powerful tool for the study of liver disease and personalized treatment Design in Humans and Animals. *Stem Cells Transl Med*. 2016;5:325–30.
 135. Handa K, Matsubara K, Fukumitsu K, Guzman-Lepe J, Watson A, Soto-Gutierrez A. Assembly of human organs from stem cells to study liver disease. *Am J Pathol*. 2014;184:348–57.
 136. Lu WY, Bird TG, Boulter L, Tsuchiya A, Cole AM, Hay T, Guest RV, Wojtacha D, Man TY, Mackinnon A, et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. *Nat Cell Biol*. 2015;17:971–83.
 137. Scheers I, Maerckx C, Khuu DN, Marcelle S, Decottignies A, Najimi M, Sokal E. Adult-derived human liver progenitor cells in long-term culture maintain appropriate gatekeeper mechanisms against transformation. *Cell Transplant*. 2012;21:2241–55.
 138. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. *Nat Rev Mol Cell Biol*. 2007;8:839–45.
 139. De Crignis E, Carofiglio F, Moulos P, Verstegen MM, Romal S, Khalid MM, Pourfarzad F, Koutsothanassis C, Gehart H, Kan TW, Palstra RJ, Boucher C, Ijzermans JMN, Huch M, Boj SF, Vries R, Clevers H, van der Laan L, Hatzis P, Mahmoudi T. Human liver organoids; a patient-derived primary model for HBV Infection and Related Hepatocellular Carcinoma; 2019. <https://doi.org/10.1101/568147>.
 140. Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, Jager M, Ponz-Sarvisé M, Tiriác H, Spector MS, et al. Organoid models of human and mouse ductal pancreatic cancer. *Cell*. 2015;160:324–38.
 141. van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell*. 2015;161:933–45.
 142. Hu H, Gehart H, Artegiani B, Lopez-Iglesias C, Dekkers F, Basak O, van Es J, Chuva de Sousa Lopes SM, Begthel H, Korving J, et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. *Cell*. 2018;175:1591–1606 e1519.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

